{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:17:53Z","timestamp":1768594673717,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"DOI":"10.7759\/cureus.94531","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T08:41:32Z","timestamp":1760431292000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Fasciitis Following SARS-CoV-2 mRNA Vaccination: Case Review and Literature Overview"],"prefix":"10.7759","author":[{"given":"Tomoya","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. (2020). Accessed. June 4, 2025: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda N","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, et al.. Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting. N Engl J Med. 2021, 385:1078-90. 10.1056\/NEJMoa2110475","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.07.025","article-title":"SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: an analysis of the Japanese Adverse Drug Event Report database","volume":"31","author":"Takada K","year":"2025","unstructured":"Takada K, Taguchi K, Samura M, et al.. SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: an analysis of the Japanese Adverse Drug Event Report database. J Infect Chemother. 2025, 31:102485. 10.1016\/j.jiac.2024.07.025","journal-title":"J Infect Chemother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova K","year":"2024","unstructured":"Faksova K, Walsh D, Jiang Y, et al.. COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024, 42:2200-11. 10.1016\/j.vaccine.2024.01.100","journal-title":"Vaccine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.03.001","article-title":"Eosinophilic fasciitis: from pathophysiology to treatment","volume":"68","author":"Ihn H","year":"2019","unstructured":"Ihn H. Eosinophilic fasciitis: from pathophysiology to treatment. Allergol Int. 2019, 68:437-9. 10.1016\/j.alit.2019.03.001","journal-title":"Allergol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-3719","article-title":"Environmental triggers of dermatomyositis: a narrative review","volume":"9","author":"Bax CE","year":"2021","unstructured":"Bax CE, Maddukuri S, Ravishankar A, Pappas-Taffer L, Werth VP. Environmental triggers of dermatomyositis: a narrative review. Ann Transl Med. 2021, 9:434. 10.21037\/atm-20-3719","journal-title":"Ann Transl Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04708-8","article-title":"Neuromuscular presentations in patients with COVID-19","volume":"41","author":"Paliwal VK","year":"2020","unstructured":"Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020, 41:3039-56. 10.1007\/s10072-020-04708-8","journal-title":"Neurol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13103","article-title":"Infectious processes and systemic lupus erythematosus","volume":"158","author":"Illescas-Montes R","year":"2019","unstructured":"Illescas-Montes R, Corona-Castro CC, Melguizo-Rodr\u00edguez L, Ruiz C, Costela-Ruiz VJ. Infectious processes and systemic lupus erythematosus. Immunology. 2019, 158:153-60. 10.1111\/imm.13103","journal-title":"Immunology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108595","article-title":"Infection-induced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis: a systematic review","volume":"220","author":"Kakoullis L","year":"2020","unstructured":"Kakoullis L, Parperis K, Papachristodoulou E, Panos G. Infection-induced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis: a systematic review. Clin Immunol. 2020, 220:108595. 10.1016\/j.clim.2020.108595","journal-title":"Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/20503121241261165","article-title":"COVID-19 vaccine-associated vasculitis: a systematic review","volume":"12","author":"Abuhammad A","year":"2024","unstructured":"Abuhammad A, Albandak M, Ayyad M, et al.. COVID-19 vaccine-associated vasculitis: a systematic review. SAGE Open Med. 2024, 12:20503121241261165. 10.1177\/20503121241261165","journal-title":"SAGE Open Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05203-3","article-title":"New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review","volume":"42","author":"Sagy I","year":"2022","unstructured":"Sagy I, Zeller L, Raviv Y, Porges T, Bieber A, Abu-Shakra M. New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review. Rheumatol Int. 2022, 42:2261-6. 10.1007\/s00296-022-05203-3","journal-title":"Rheumatol Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-023-09368-2","article-title":"COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report","volume":"71","author":"Syrmou V","year":"2023","unstructured":"Syrmou V, Liaskos C, Ntavari N, et al.. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunol Res. 2023, 71:537-46. 10.1007\/s12026-023-09368-2","journal-title":"Immunol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1007637","article-title":"Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review","volume":"10","author":"Ding Y","year":"2022","unstructured":"Ding Y, Ge Y. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. Front Public Health. 2022, 10:1007637. 10.3389\/fpubh.2022.1007637","journal-title":"Front Public Health"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.02.008","article-title":"Sclerotic skin disease development following COVID-19 vaccination","volume":"22","author":"Sprow G","year":"2022","unstructured":"Sprow G, Dan J, Abbott J, et al.. Sclerotic skin disease development following COVID-19 vaccination. JAAD Case Rep. 2022, 22:74-7. 10.1016\/j.jdcr.2022.02.008","journal-title":"JAAD Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10768-3","article-title":"COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis","volume":"269","author":"Faissner S","year":"2022","unstructured":"Faissner S, Richter D, Ceylan U, Schneider-Gold C, Gold R. COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis. J Neurol. 2022, 269:1774-5. 10.1007\/s00415-021-10768-3","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.11.038","article-title":"Eosinophilic fasciitis following SARS-CoV-2 vaccination","volume":"36","author":"Antu\u00f1a VL","year":"2023","unstructured":"Antu\u00f1a VL, Puchades F, Tapial JM, Ribelles JC, Sanz F, Tamarit JJ. Eosinophilic fasciitis following SARS-CoV-2 vaccination. JAAD Case Rep. 2023, 36:11-4. 10.1016\/j.jdcr.2022.11.038","journal-title":"JAAD Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2022.e01475","article-title":"Fasciitis of the lower leg after COVID-19 vaccination","volume":"28","author":"Ide S","year":"2022","unstructured":"Ide S, Kurozumi A, Takeshige A, Shimomura A, Watanabe R, Inagaki T. Fasciitis of the lower leg after COVID-19 vaccination. IDCases. 2022, 28:e01475. 10.1016\/j.idcr.2022.e01475","journal-title":"IDCases"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15410","article-title":"Covid-19 vaccine associated erythema nodosum: factors to consider","volume":"35","author":"Damevska K","year":"2022","unstructured":"Damevska K, Simeonovski V. Covid-19 vaccine associated erythema nodosum: factors to consider. Dermatol Ther. 2022, 35:e15410. 10.1111\/dth.15410","journal-title":"Dermatol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16974","article-title":"Erythema nodosum after COVID-19 vaccine associated with varicella-zoster virus reactivation","volume":"63","author":"Kobayashi E","year":"2024","unstructured":"Kobayashi E, Ohyama M, Yamazaki Y, Mizukawa Y. Erythema nodosum after COVID-19 vaccine associated with varicella-zoster virus reactivation. Int J Dermatol. 2024, 63:e44-6. 10.1111\/ijd.16974","journal-title":"Int J Dermatol"},{"key":"ref20","unstructured":"Interim clinical considerations for use of COVID-19 vaccines in the United States. (2025). Accessed. September 1, 2025: https:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/418604-a-case-of-fasciitis-following-sars-cov-2-mrna-vaccination-case-review-and-literature-overview","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T08:41:35Z","timestamp":1760431295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/418604-a-case-of-fasciitis-following-sars-cov-2-mrna-vaccination-case-review-and-literature-overview"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.94531","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}